Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases

Detalhes bibliográficos
Autor(a) principal: Ferreira, Sandra
Data de Publicação: 2021
Outros Autores: Fernandes, Iolanda, Cabral, Renata, Lima, Margarida
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.29021/spdv.79.1.1277
Resumo: Brentuximab vedotin is approved by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of adult patients with CD30-positive primary cutaneous T-cell lymphomas, refractory to at least one previous line of therapy. The authors report two clinical cases of primary cutaneous anaplastic large-cell lymphoma treated with brentuximab vedotin, with different clinical responses. Nevertheless, brentuximab vedotin may be a valid therapeutic alternative for the treatment of these pathologies.
id RCAP_03f516a3228ab99aa6589a9fc8b35df7
oai_identifier_str oai:ojs.revista.spdv.com.pt:article/1277
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical CasesTratamento do Linfoma Cutâneo Primário de Células Grandes Anaplásicas com Brentuximab Vedotina: A Propósito de Dois Casos ClínicosBrentuximab VedotinLymphoma, Primary Cutaneous Anaplastic Large Cell/drug therapyLymphoma, T-CellCutaneous/drug therapySkin Neoplasms/drug therapyBrentuximab VedotinaLinfoma Cutâneo Primário de Células Grandes Anaplásicas/tratamento farmacológicoLinfoma Cutâneo de Células T/tratamento farmacológicoNeoplasias da Pele/tratamento farmacológicoBrentuximab vedotin is approved by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of adult patients with CD30-positive primary cutaneous T-cell lymphomas, refractory to at least one previous line of therapy. The authors report two clinical cases of primary cutaneous anaplastic large-cell lymphoma treated with brentuximab vedotin, with different clinical responses. Nevertheless, brentuximab vedotin may be a valid therapeutic alternative for the treatment of these pathologies.O brentuximab vedotina está aprovado pela Food and Drug Administration (FDA) e pela European Medicines Agency (EMA) para o tratamento de doentes adultos com linfomas cutâneos primários de células T CD30+, refratários a pelo menos uma linha terapêutica prévia. Os autores reportam dois casos clínicos de linfoma cutâneo primário de células grandes anaplásicas, tratados com brentuximab vedotina, com respostas clínicas distintas. Não obstante, o brentuximab vedotina poderá constituir uma alternativa terapêutica válida para o tratamento destas patologias.Sociedade Portuguesa de Dermatologia e Venereologia2021-04-05T00:00:00Zjournal articleinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://doi.org/10.29021/spdv.79.1.1277oai:ojs.revista.spdv.com.pt:article/1277Journal of the Portuguese Society of Dermatology and Venereology; Vol 79 No 1 (2021): January - March; 53-56Revista da Sociedade Portuguesa de Dermatologia e Venereologia; v. 79 n. 1 (2021): Janeiro - Março; 53-562182-24092182-2395reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revista.spdv.com.pt/index.php/spdv/article/view/1277https://doi.org/10.29021/spdv.79.1.1277https://revista.spdv.com.pt/index.php/spdv/article/view/1277/886Copyright (c) 2021 Journal of the Portuguese Society of Dermatology and Venereologyhttps://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessFerreira, SandraFernandes, IolandaCabral, RenataLima, Margarida2022-10-06T12:35:17Zoai:ojs.revista.spdv.com.pt:article/1277Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:11:18.233620Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases
Tratamento do Linfoma Cutâneo Primário de Células Grandes Anaplásicas com Brentuximab Vedotina: A Propósito de Dois Casos Clínicos
title Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases
spellingShingle Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases
Ferreira, Sandra
Brentuximab Vedotin
Lymphoma, Primary Cutaneous Anaplastic Large Cell/drug therapy
Lymphoma, T-Cell
Cutaneous/drug therapy
Skin Neoplasms/drug therapy
Brentuximab Vedotina
Linfoma Cutâneo Primário de Células Grandes Anaplásicas/tratamento farmacológico
Linfoma Cutâneo de Células T/tratamento farmacológico
Neoplasias da Pele/tratamento farmacológico
title_short Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases
title_full Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases
title_fullStr Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases
title_full_unstemmed Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases
title_sort Treatment of Primary Cutaneous Anaplastic Large-Cell Lymphoma with Brentuximab Vedotin: Report of Two Clinical Cases
author Ferreira, Sandra
author_facet Ferreira, Sandra
Fernandes, Iolanda
Cabral, Renata
Lima, Margarida
author_role author
author2 Fernandes, Iolanda
Cabral, Renata
Lima, Margarida
author2_role author
author
author
dc.contributor.author.fl_str_mv Ferreira, Sandra
Fernandes, Iolanda
Cabral, Renata
Lima, Margarida
dc.subject.por.fl_str_mv Brentuximab Vedotin
Lymphoma, Primary Cutaneous Anaplastic Large Cell/drug therapy
Lymphoma, T-Cell
Cutaneous/drug therapy
Skin Neoplasms/drug therapy
Brentuximab Vedotina
Linfoma Cutâneo Primário de Células Grandes Anaplásicas/tratamento farmacológico
Linfoma Cutâneo de Células T/tratamento farmacológico
Neoplasias da Pele/tratamento farmacológico
topic Brentuximab Vedotin
Lymphoma, Primary Cutaneous Anaplastic Large Cell/drug therapy
Lymphoma, T-Cell
Cutaneous/drug therapy
Skin Neoplasms/drug therapy
Brentuximab Vedotina
Linfoma Cutâneo Primário de Células Grandes Anaplásicas/tratamento farmacológico
Linfoma Cutâneo de Células T/tratamento farmacológico
Neoplasias da Pele/tratamento farmacológico
description Brentuximab vedotin is approved by the Food and Drug Administration (FDA) and by the European Medicines Agency (EMA) for the treatment of adult patients with CD30-positive primary cutaneous T-cell lymphomas, refractory to at least one previous line of therapy. The authors report two clinical cases of primary cutaneous anaplastic large-cell lymphoma treated with brentuximab vedotin, with different clinical responses. Nevertheless, brentuximab vedotin may be a valid therapeutic alternative for the treatment of these pathologies.
publishDate 2021
dc.date.none.fl_str_mv 2021-04-05T00:00:00Z
dc.type.driver.fl_str_mv journal article
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.29021/spdv.79.1.1277
oai:ojs.revista.spdv.com.pt:article/1277
url https://doi.org/10.29021/spdv.79.1.1277
identifier_str_mv oai:ojs.revista.spdv.com.pt:article/1277
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://revista.spdv.com.pt/index.php/spdv/article/view/1277
https://doi.org/10.29021/spdv.79.1.1277
https://revista.spdv.com.pt/index.php/spdv/article/view/1277/886
dc.rights.driver.fl_str_mv Copyright (c) 2021 Journal of the Portuguese Society of Dermatology and Venereology
https://creativecommons.org/licenses/by-nc/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 Journal of the Portuguese Society of Dermatology and Venereology
https://creativecommons.org/licenses/by-nc/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Dermatologia e Venereologia
publisher.none.fl_str_mv Sociedade Portuguesa de Dermatologia e Venereologia
dc.source.none.fl_str_mv Journal of the Portuguese Society of Dermatology and Venereology; Vol 79 No 1 (2021): January - March; 53-56
Revista da Sociedade Portuguesa de Dermatologia e Venereologia; v. 79 n. 1 (2021): Janeiro - Março; 53-56
2182-2409
2182-2395
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130568514863104

Registros relacionados